Mundipharma & Helsinn expand licensing and distribution agreement to include Vietnam
Mundipharma and Helsinn Group have extended their licensing and distribution agreement for the anti-emetic agent ALOXI to now include Vietnam.
ALOXI — palonosetron hydrochloride — is a 5-HT3 receptor antagonist that is indicated for the treatment of nausea and vomiting induced by chemotherapy and for the prevention of nausea and vomiting after an operation (for up to 24 hours).
Chemotherapy-Induced Nausea and Vomiting (CINV) is one of the most common and distressing side effects of cancer chemotherapy. Mundipharma and Helsinn are experts in the CINV field with decades of shared experience and are currently providing medicine to CINV sufferers.
Mundipharma CEO, Raman Singh said: “This important extension of our portfolio in Vietnam offers relief to patients suffering from the side effects of chemotherapy and enables patients and healthcare providers to benefit from our expertise in this area.”
“Helsinn and Mundipharma have an effective, longstanding partnership and Mundipharma successfully markets, promotes and distributes a number of our products across a range of territories,” commented Riccardo Braglia, Helsinn Group Vice Chairman and CEO. “We’re delighted to be able to extend this relationship through this agreement.”
Helsinn is a privately owned pharmaceutical group with an extensive portfolio of marketed cancer care products and a robust drug development pipeline.
Mundipharma is a network of independent associated companies, which are privately owned entities, covering pharmaceutical markets in Asia-Pacific, Latin America, the Middle East and Africa.